Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis

Cellular Markers During a Non-tuberculous Mycobacterial Respiratory Infection, Treated or Untreated, in Patients With Cystic Fibrosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study evaluates a diagnostic serological test for Non-Tuberculous Mycobacteria (NTM) infection in cystic fibrosis patients by measuring T cell response. It aims to highlight a dynamic response associated to the pathogen's presence. This multicenter case-control study involves two populations, providing a better understanding of the circulating T-IFNγ-MNT response in these patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient ≥18 years - Patient previously included in the CIMeNT study - Patient with a confirmed diagnosis of cystic fibrosis regardless of CFTR genotype - Patient affiliated to the social security system - Patient registered in the French Cystic Fibrosis Registry - Adult patient capable of spontaneous expectoration or after induction Who Should NOT Join This Trial: - Lung transplant patients - Person placed under judicial protection - Pregnant and breastfeeding women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient ≥18 years * Patient previously included in the CIMeNT study * Patient with a confirmed diagnosis of cystic fibrosis regardless of CFTR genotype * Patient affiliated to the social security system * Patient registered in the French Cystic Fibrosis Registry * Adult patient capable of spontaneous expectoration or after induction Exclusion Criteria: * Lung transplant patients * Person placed under judicial protection * Pregnant and breastfeeding women

Treatments Being Tested

OTHER

Scheduled visit (V1)

During the scheduled visit (V1), as part of routine care, a blood draw will be performed. On this occasion, an additional 7 ml tube will be collected to perform serology and culture. This will help define the group (NTM+ Cases/NTM- Controls) and measure cellular biomarkers.

Locations (1)

CHU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France